Keminntek Pharmaceuticals Llp - Company Profile

It is a pharma limited liability partnership based in Hyderabad, Telangana, India, established in 2018.
2018 Hyderabad, Telangana, India Active
Last Updated:
Access Report
About Keminntek Pharmaceuticals Llp

Keminntek Pharmaceuticals Llp, a active limited liability partnership, was established on 13 November 2018 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the pharma sector, it holds LLPIN: AAN-5408. Registered under ROC Roc Hyderabad. It has total obligation of contribution of ₹1.00 M.

Its leadership includes Sreenivas Peddolla (Designated Partner), Srinivas Kolupula (Designated Partner). Its latest date of accounts and solvency statement 31 March 2020. It is based at H. No: 9-94/7 Plot No. 76, Laxmi Nagar Colony Boduppal, Medchal, Hyderabad, Telangana, 500039.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    AAN-5408

  • Incorporation Date

    13 November 2018

  • Total Obligation of Contribution

    ₹1.00 M

  • ROC Code

    Roc Hyderabad

  • Company Status

    Active

Key Metrics
  • Obligation of Contribution ₹ 1.00 M
  • Company Age 7 Year, 4 Months
  • Last Filing with ROC 31 Mar 2020
  • Revenue Growth **** %
  • Profit Growth **** -37.53%
  • Ebitda ****
  • Total Assets **** 50.93%
Company report

Keminntek Pharmaceuticals Llp

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Keminntek Pharmaceuticals Llp — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Keminntek Pharmaceuticals Llp?
Current Designated Partners
Name Designation Appointment Date Status
Sreenivas Peddolla Designated Partner 13 Nov 2018 Current
Srinivas Kolupula Designated Partner 13 Nov 2018 Current

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Keminntek Pharmaceuticals Llp.

Keminntek Pharmaceuticals Llp, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 37.53% decrease in profit. The company's net worth witnessed no change by increase of 0%.

Keminntek Pharmaceuticals Llp revenue growth over time
Keminntek Pharmaceuticals Llp profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
 50.93%
*******
*******
*******
*******
Profit or Loss
*******
 -37.53%
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Keminntek Pharmaceuticals Llp?

Unlock access to Keminntek Pharmaceuticals Llp's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Keminntek Pharmaceuticals Llp?

Unlock and access historical data on people associated with Keminntek Pharmaceuticals Llp, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Keminntek Pharmaceuticals Llp, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Keminntek Pharmaceuticals Llp's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Keminntek Pharmaceuticals Llp
Recent Activity within the Organization
  • Annual General Meeting

    Keminntek Pharmaceuticals Llp last Annual general meeting of members was held on 31 Mar 2021 as per latest MCA records. was recorded as a recent event.

  • Statement of Assets & Liabilities

    Keminntek Pharmaceuticals Llp has filed its annual Financial statements for the year ended 31 Mar 2020 with Roc Hyderabad. was recorded as a recent event.

  • Director Appointment

    The activity Sreenivas Peddolla was appointed as a Designated Partner was appointed as a Designated Partner on 13 Nov 2018 & has been associated with this company since 7 years 4 months . was completed.

  • Director Appointment

    Srinivas Kolupula was appointed as a Designated Partner was appointed as a Designated Partner on 13 Nov 2018 & has been associated with this company since 7 years 4 months . was recorded as a recent event.

  • LLP Incorporation

    The activity Keminntek Pharmaceuticals Llp was registered on 13 Nov 2018 with Roc Hyderabad & aged 7 years 4 months as per MCA records. was completed.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the LLPIN of Keminntek Pharmaceuticals Llp?

The LLPIN of Keminntek Pharmaceuticals Llp is AAN-5408.

Where is Keminntek Pharmaceuticals Llp headquartered?

Keminntek Pharmaceuticals Llp is headquartered at H. No: 9-94/7 Plot No. 76, Laxmi Nagar Colony Boduppal, Medchal, Hyderabad, Telangana, 500039.

When was Keminntek Pharmaceuticals Llp incorporated?

Keminntek Pharmaceuticals Llp was incorporated on 13 November 2018.

Who are the current directors of Keminntek Pharmaceuticals Llp?

The current directors of Keminntek Pharmaceuticals Llp are

What is the primary industry of Keminntek Pharmaceuticals Llp?

The primary industry of Keminntek Pharmaceuticals Llp is Pharma.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available